# Correction to: Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

PMC · DOI: 10.1093/oncolo/oyaf119 · The Oncologist · 2025-05-30

## Full-text entities

- **Diseases:** Colorectal Cancer (MESH:D015179)
- **Chemicals:** Bevacizumab (MESH:D000068258), TAS-102 (MESH:C000613803)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12124116/full.md

---
Source: https://tomesphere.com/paper/PMC12124116